Tigecycline and Comparators Against S. pneumoniae: A Global Study

Objectives: S. pneumoniae (SPN) continues to be recognized as a significant respiratory and bacteremic pathogen. Resistance to both oral and parenteral antibiotics used to treat SPN infection is evolving and newer antibiotics are needed with anti-SPN activity. This report documents the activity of tigecycline and comparators against 5501 SPN collected globally since 2004. Methods: Between 2004—2007, 387 hospital sites in 48 countries collected 5501 SPN deemed clinically significant from a variety of sources. MICs were determined at each site using supplied broth microdilution panels and MIC results interpreted by CLSI standards at each site. Results: The % SPN inhibited at each MIC are shown below: Conclusions: Tigecycline demonstrated excellent in vitro activity against SPN with 100% of isolates inhibited at ≤0.5 mcg/ml. Globally, only 61.5% of SPN were susceptible to penicillin, while 0.2% were resistant to levofloxacin. Continued surveillance of resistance in SPN to new and established antimicrobials is warranted.